LONG MINI-FUTURE - VERTEX PHARMACEUTICALS | Market Closed - Deutsche Boerse AG 14:01:43 2024-06-21 EDT | ||
| 11.61 EUR | -3.81% |
|
| Current month | +15.06% | ||
| 1 month | +29.43% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 11.61 | -3.81% |
| 24-06-20 | 12.07 | +5.88% |
| 24-06-19 | 11.4 | -3.14% |
| 24-06-18 | 11.77 | -5.46% |
| 24-06-17 | 12.45 | -3.64% |
Delayed Quote Deutsche Boerse AG
Last update June 21, 2024 at 02:01 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VU8GFS |
| ISIN | DE000VU8GFS9 |
| Date issued | 2023-06-13 |
| Strike | 345.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.22 € |
|---|---|
| Lowest since issue | 0.66 € |
| Spread | 0.04 € |
| Spread % | 0.34% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
468.7
USD
Average target price
463.4
USD
Spread / Average Target
-1.13%
- Stock Market
- Certificates
- Certificat
